Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $20.69 Analyst target: $2.00 Upside: -90.33%
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company is headquartered in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
See the full interactive analysis & chart →Informational only — not investment advice.